VenatoRx has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs.
VenatoRx received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.
VenatoRx was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M.
In the report, Carbapenem Resistant Enterobacteriaceae was classified as an Urgent treat.
VenatoRx was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. VenatoRx may receive up to $3M of funding under the grant.
Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma.
Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital.